Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14012809 | 1.00 | SIGMAR1 (0.51) | SIGMAR1MAPTGBA1HDAC11SPHK2 | |
| SCHEMBL15593209 | 1.00 | SIGMAR1 (0.51) | SIGMAR1MAPTGBA1HDAC11SPHK2 | |
| SCHEMBL5372095 | 0.87 | MAPT (0.43) | SIGMAR1MAPT | |
| SCHEMBL16399825 | 0.86 | SIGMAR1 (0.46) | SIGMAR1MAPTGBA1HDAC11 | |
| SCHEMBL14570526 | 0.85 | CFB (0.39) | SIGMAR1MAPTGBA1SPHK2SPHK1 | |
| SCHEMBL29105856 | 0.84 | CTSL (0.49) | SIGMAR1MAPTGBA1HDAC11SPHK2 | |
| SCHEMBL14038287 | 0.83 | SIGMAR1 (0.37) | SIGMAR1MAPTGBA1SPHK2SPHK1 | |
| SCHEMBL22399622 | 0.81 | HDAC11 (0.43) | SIGMAR1MAPTGBA1HDAC11SPHK2 | |
| SCHEMBL31309170 | 0.80 | SIGMAR1 (0.42) | SIGMAR1MAPTGBA1HDAC11SPHK2 | |
| SCHEMBL18387532 | 0.80 | SIGMAR1 (0.42) | SIGMAR1MAPTGBA1HDAC11SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080274107-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-11-06 | — | — | US | disclosed |
| US-20080274107-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-11-06 | — | — | US | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080274107-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | SIGMAR1 3990/4885MAPT 1182/4885GBA1 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.